Anhui Shi, Md

This study looked at 45 people with limited-stage small-cell lung cancer who received the immunotherapy drug durvalumab after standard chemoradiotherapy. The goal was to see how long the cancer stayed under control and how safe the treatment was. Results from this real-world anal…